Deadlines are 5:00 PM (Eastern). No extensions will be granted.
|Letter of Intent Required||Jun 21, 2022||Passed|
|Application||Aug 23, 2022||Next|
|Award Notification||Feb 28, 2023|
|Earliest Start||Apr 01, 2023|
Background & Purpose
Please click on the “RFA Announcement” link for complete information.
JDRF is committed to accelerating the development of therapies that can complement insulin (i.e., adjunctive therapies) to improve glucose and metabolic outcomes in people with type 1 diabetes (T1D). To this end, we invite applications that propose (1) clinical trials to evaluate glucometabolic therapies in people with T1D or (2) mechanistic clinical studies to advance our knowledge of glucometabolic control in T1D toward the goal of future therapy development.
Insulin is required for all people with T1D. However, for most people, insulin monotherapy is insufficient for optimal glucose control. Further, a growing body of evidence is demonstrating the contribution of non-glucose metabolic imbalances like insulin resistance and obesity to long-term complications in T1D. Since insulin is powerless to address these and other challenges, adjunctive therapies must be developed to address both glucose and broader metabolic control. Despite the urgent need, only one adjunctive therapy (pramlintide) currently has regulatory approval in the US. Barriers to the development of adjunctive therapies for T1D glucometabolic control include an evidence gap for how existing and emerging therapies for type 2 diabetes, obesity, and other indications affect outcomes in T1D, lack of knowledge about specific mechanisms underlying glucometabolic imbalances in T1D, and limited commercial investment. This RFA is intended to support (1) clinical trials testing therapies—novel or repositioned, approved or in clinical development— for glucometabolic control in T1D, or (2) mechanistic clinical research to inform a better understanding of T1D glucometabolic imbalances to enable future therapy development.